Skip to Main Content

Paper Details

Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Clin Infect Dis
26
2021
AIDS, CYP2B6, CYP2B6 genotype, Efavirenz, HIV, INSTI, Integrase, UGT1A1, UGT1A1 genotype, UGT1A1 genotypes, abacavir, dolutegravir, efavirenz, elvitegravir, human immunodeficiency virus, integrase, nucleoside, participants, patients, people, raltegravir, tenofovir disoproxil fumarate
Author NameAffiliation
Yuki BradfordUniversity of Pennsylvania
Todd HulganVanderbilt University Medical Center
Eric S DaarLundquist Institute at Harbor-university of california los angeles Medical Center
Roy M Gulick
Sharon A RiddlerUniversity of Pittsburgh
Marylyn D RitchieUniversity of Pennsylvania
Marylyn D RitchieInstitute for Biomedical Informatics, University of Pennsylvania
Marylyn D RitchieUniversity of Pennsylvania
Marylyn D RitchieInstitute for Biomedical Informatics, University of Pennsylvania
David W HaasVanderbilt University Medical Center
David W HaasMeharry Medical College
David W HaasVanderbilt University Medical Center
David W HaasMeharry Medical College
  • 1 - 13

Datasets

Release 1.2